13F Pro

SEC Form 4 reporting owner

Kaye Edward M. MD

Kaye Edward M. MD has filed 22 Form 4 transactions reported between December 1, 2025 and August 18, 2026, as a reporting owner of Stoke Therapeutics, Inc., Director of CYTOKINETICS INC and a reporting owner of Avidity Biosciences, Inc..

Name as filed: Kaye Edward M. MD

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$2.5M
4 lines
Companies
3
with Form 4 filings
Latest transaction
Aug 18, 2026
transaction date

Roles and reported holdings

  • STOKStoke Therapeutics, Inc.
    Mar 15, 2026 – Aug 18, 2026

    Reporting owner

    Held directly124,557 sh as of Aug 18, 2026 · Form 4

    24 months: $403K sold

  • CYTKCYTOKINETICS INC
    Dec 1, 2025 – Jul 15, 2026

    Director

    Held directly10,283 sh as of Jun 1, 2026 · Form 4

    24 months: $2.1M sold

  • RNAAvidity Biosciences, Inc.
    Feb 27, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 22 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Aug 18, 2026STOKOpen-market saleCode S · direct637$21K@ $32.47Form 4
Aug 18, 2026STOKOpen-market saleCode S · direct11,930$382K@ $32.01Form 4
Aug 14, 2026STOKOption exerciseCode M · direct26,250—Form 4
Jul 15, 2026CYTKDirectorGrant or awardCode A · direct151$12K@ $82.62Form 4
Jun 3, 2026STOKGrant or awardCode A · direct17,786—Form 4
Jun 1, 2026CYTKDirectorOpen-market saleCode S · direct2,933$223K@ $76.09Form 4
May 27, 2026CYTKDirectorGrant or awardCode A · direct4,301—Form 4
May 27, 2026CYTKDirectorGrant or awardCode A · direct2,851—Form 4
Apr 15, 2026CYTKDirectorGrant or awardCode A · direct191$12K@ $65.37Form 4
Mar 15, 2026STOKOption exerciseCode M · direct26,250—Form 4
Mar 15, 2026STOKOption exerciseCode M · direct35,500—Form 4
Feb 27, 2026RNADisposition to issuerCode D · direct9,534—Form 4
Feb 27, 2026RNADisposition to issuerCode D · direct11,323—Form 4
Feb 27, 2026RNADisposition to issuerCode D · direct15,000—Form 4
Feb 27, 2026RNADisposition to issuerCode D · direct22,000—Form 4
Feb 27, 2026RNADisposition to issuerCode D · direct13,489—Form 4
Feb 27, 2026RNADisposition to issuerCode D · direct10,034—Form 4
Feb 27, 2026RNADisposition to issuerCode D · direct6,692—Form 4
Jan 15, 2026CYTKDirectorGrant or awardCode A · direct197$12K@ $63.44Form 4
Dec 1, 2025CYTKDirectorOpen-market saleCode S · direct28,064$1.9M@ $66.72Form 4
Dec 1, 2025CYTKDirectorOption exerciseCode M · direct20,000$285K@ $14.25Form 4
Dec 1, 2025CYTKDirectorOption exerciseCode M · direct8,064$100K@ $12.40Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.